drugset / Trial / NCT03758924
Study of ANAVEX2-73 in Patients With Rett Syndrome
Phase 2
Completed
31 enrolled
Anavex Life Sciences Corp.
International Rett Syndrome Foundation · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
Phase 2 safety, tolerability and efficacy study is designed as a double-blind, randomized, placebo-controlled study. 7-week placebo-controlled study of ANAVEX2-73 oral solution for the treatment of patients with RTT 18 years or older. A voluntary option will be offered for all patients who meet the exposure criteria for ANAVEX2-73 to continue a 12-week open label extension.
Timeline
- Start
- 2019-02-28
- Primary completion
- 2020-10-30
- Completion
- 2020-10-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Blarcamesine | Small molecule | 1 ml | Oral |